Palvella (PVLA) CFO exercises stock options, adds 1,000 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Palvella Therapeutics CFO Matthew E. Korenberg exercised stock options to acquire 1,000 shares of common stock at $13.60 per share. Following the transaction, he directly owns 1,000 common shares and retains stock options covering 166,100 shares.

The exercised options have an exercise price of $13.60 and an expiration date of December 13, 2034. According to the vesting terms, 25% of the options vest on October 16, 2025, with the remaining 75% vesting in equal monthly tranches over the next 36 months.

Insider Trade Summary

1,000 shares exercised/converted

Mixed 2 txns

Insider Korenberg Matthew E

Role CFO, Treasurer

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	1,000	$0.00	--
Exercise	Common Stock	1,000	$13.60	$14K

Holdings After Transaction: Stock Option (Right to Buy) — 166,100 shares (Direct, null); Common Stock — 1,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares acquired: 1,000 shares Exercise price: $13.60 per share Shares owned after: 1,000 shares +4 more

7 metrics

Shares acquired 1,000 shares Common stock acquired via option exercise on June 12, 2026

Exercise price $13.60 per share Stock option exercise price for 1,000 shares

Shares owned after 1,000 shares Direct common stock holdings after the transaction

Options remaining 166,100 options Stock options outstanding after the exercise

Option expiration December 13, 2034 Expiration date of the reported stock options

Initial vesting 25% on October 16, 2025 First tranche of option vesting

Remaining vesting period 36 months Remaining 75% vests in equal monthly tranches

Key Terms

Stock Option (Right to Buy), Exercise or conversion of derivative security, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

vesting financial

"25% of the stock options will vest on October 16, 2025"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2034-12-13T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/16/2026 - 04:07 PM Accepted by SEC EDGAR 06/16/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Korenberg Matthew E

(Last)

(First)

(Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO, Treasurer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/12/2026		M		1,000	A	$13.6	1,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$13.6	06/12/2026		M			1,000	⁽¹⁾	12/13/2034	Common Stock	1,000	$0	166,100	D

Explanation of Responses:

1. 25% of the stock options will vest on October 16, 2025, and the remaining 75% will vest in equal monthly tranches over the following 36 months.

	/s/ Kathleen A. McGowan, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Palvella Therapeutics (PVLA) disclose?

Palvella Therapeutics reported that CFO Matthew E. Korenberg exercised stock options to acquire 1,000 shares of common stock at $13.60 per share, increasing his directly held share position in the company.

How many Palvella (PVLA) shares does the CFO hold after this Form 4?

After the transaction, CFO Matthew E. Korenberg directly owns 1,000 shares of Palvella Therapeutics common stock. He also retains stock options representing 166,100 underlying shares, providing additional potential equity exposure.

What was the exercise price in the Palvella (PVLA) CFO option exercise?

The exercised stock options had an exercise price of $13.60 per share. Exercising at this fixed price converts the options into common shares, giving the CFO actual share ownership instead of just option rights.

What stock option vesting schedule applies to Palvella (PVLA) CFO awards?

For the referenced option grant, 25% of the stock options vest on October 16, 2025. The remaining 75% vest in equal monthly tranches over the following 36 months, creating a multi-year incentive schedule.

When do the Palvella Therapeutics (PVLA) CFO stock options expire?

The stock options related to this transaction carry an expiration date of December 13, 2034. After that date, any unexercised options from this grant will no longer be exercisable into common shares.